|
| Press Releases |
|
 |
|
| Thursday, March 30, 2023 |
|
|
Apollomics, a Company Developing Novel Oncology Therapies to Address Difficult-to-Treat Cancers, Announces Closing of Business Combination and Listing on Nasdaq |
| Apollomics Inc. ("Apollomics" or the "Company"), a clinical-stage biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, today announced the completion of its business combination (the "Business Combination") with Maxpro Capital Acquisition Corp. ("Maxpro", Nasdaq: JMAC). more info >> |
|
| Tuesday, July 26, 2022 |
|
|
Apollomics Inc. Expands Leadership Team with Appointment of Jane Wang, PhD as Chief Scientific Officer |
| Apollomics Inc. an innovative biopharmaceutical company committed to the discovery and development of mono- and combination- oncology therapies, today announced the appointment of Jane Wang, PhD as Chief Scientific Officer. In this role, Dr. Wang will lead the drug discovery pipeline for the Company. She will also serve as Apollomics' China General Manager and will report to the Chief Executive Officer. more info >> |
|
| Wednesday, January 12, 2022 |
|
|
Apollomics Inc. to Host Virtual Investor Events on Wednesday, January 26, 2022 and Thursday, January 27, 2022 |
| Apollomics Inc. an innovative biopharmaceutical company committed to the discovery and development of mono- and combination- oncology therapies, today announced that the management team will host two upcoming webcasts to accommodate participants from the U.S. and China. more info >> |
|
| Tuesday, January 4, 2022 |
|
|
Apollomics Inc. Announces CEO Guo-Liang Yu, PhD Appointed as Chairman of the Board for the BayHelix Group |
| Apollomics Inc., an innovative biopharmaceutical company committed to the discovery and development of mono- and combination- oncology therapies, today announced that Guo-Liang Yu, PhD, Co-Founder, Chairman and Chief Executive Officer of Apollomics, was recently appointed to Chairman of the Board for the BayHelix Group, effective January 2022. more info >> |
|
| Monday, November 22, 2021 |
|
|
Apollomics Inc. Doses First Patient in Phase 3 Clinical Trial with APL-106 (Uproleselan Injection) in Chinese Patients with Relapsed/Refractory Acute Myeloid Leukemia |
| Apollomics Inc., an innovative biopharmaceutical company committed to the discovery and development of mono- and combination- oncology therapies, today announced that the first patient has been successfully dosed in a Phase 3 clinical trial of APL-106 (uproleselan injection) for the treatment of adults with relapsed or refractory acute myeloid leukemia (AML) in China. more info >> |
|
| Friday, October 1, 2021 |
|
|
Edison Oncology and Apollomics Announce Treatment of First Patient by EO1001 (APL-122) in a Phase I/IIa Clinical Trial |
| Edison Oncology Holding Corp. ('Edison Oncology'), a company established to develop new therapies targeting the fight against cancer, and Apollomics Inc. ('Apollomics'), an innovative biopharmaceutical company committed to the discovery and development of mono- and combination oncology therapies, reported that the first patient was dosed with EO1001 (APL-122) in a Phase I/IIa clinical trial in patients with advanced solid tumors. more info >> |
|
| Tuesday, August 10, 2021 |
|
|
Apollomics, Inc. Doses First Patient in a Phase I Clinical Trial of APL-102 |
| Apollomics Inc., an innovative biopharmaceutical company committed to the discovery and development of mono- and combination oncology therapies, today announced the successful dosing of the first patient in a Phase I clinical study of APL-102 in patients with advanced solid tumors. more info >> |
|
| Thursday, May 20, 2021 |
|
|
APOLLOMICS INC. ANNOUNCES OFFICIAL OPENING OF SHANGHAI BRANCH |
| Apollomics Inc., an innovative biopharmaceutical company committed to the discovery and development of mono- and combination- oncology therapies, today announced that Apollomics Shanghai Branch has been officially opened and started its operations at Zhangjiang Hi-Tech Park, Pudong District, Shanghai. more info >> |
|
| Tuesday, March 9, 2021 |
|
|
Apollomics, Inc. Appoints Seasoned Healthcare Executive K. Peony Yu, M.D., as Chief Medical Officer |
| Apollomics, Inc., an innovative biopharmaceutical company committed to the discovery and development of mono- and combination- oncology therapies, today announced the appointment of K. Peony Yu, M.D. as Chief Medical Officer. Dr. Yu will assume the role on March 16, 2021. more info >> |
|
| Thursday, March 4, 2021 |
|
|
Apollomics, Inc Announces Enrollment of First Patient in Phase 1 Clinical Trial of APL-106 (uproleselan injection) in China |
| Apollomics, Inc., an innovative biopharmaceutical company committed to the discovery and development of mono- and combination- oncology therapies, today announced that the first patient has been successfully enrolled into a Phase 1 clinical trial of APL-106 (uproleselan injection) for the treatment of adults with relapsed or refractory acute myeloid leukemia (AML) in China. In February of this year, the two Phase 1 study sites were initiated. more info >> |
|
|
|
|
|
|
|
|
 |
| Latest Press Releases |
|
Where is the next Chinese drug that will make MNCs compete to grab orders?
Jan 10, 2025 12:00 HKT/SGT
|
|
|
JCB unveils a new e-book that empowers merchants and acquirers to harness growth drivers in the European region
Jan 10, 2025 12:00 JST
|
|
|
NEC and Biomy Partner to Develop and Expand AI-Based Analytical Platforms in the Digital Pathology Field 
Jan 10, 2025 11:37 JST
|
|
|
Outlander PHEV Tops Canada's Plug-In Hybrid EV Sales in 2024
Jan 10, 2025 9:25 JST
|
|
|
CONTIOCEAN OFFICIALLY LISTED ON THE MAIN BOARD OF THE HONG KONG STOCK EXCHANGE
Jan 9, 2025 19:56 HKT/SGT
|
|
|
Over 80,000 international buyers at HKTDC's first three trade fairs in 2025
Jan 9, 2025 19:06 HKT/SGT
|
|
|
Education & Careers Expo opens next Thursday
Jan 9, 2025 18:12 HKT/SGT
|
|
|
Strengthening Supply Chains for a Sustainable Future
Jan 9, 2025 17:44 HKT/SGT
|
|
|
Stableton, Swiss Leader in VC Direct Secondaries, Partners with Alta to Expand Access to Global High-Growth Pre-IPO Investments
Jan 9, 2025 15:30 HKT/SGT
|
|
|
'Think Business, Think Hong Kong' opened doors to more fruitful, sustainable Hong Kong-Indonesia partnership
Jan 9, 2025 15:17 HKT/SGT
|
|
|
Ho Chi Minh to Host Asia's Longest Running Sustainability Event - The 17th Annual Global CSR & ESG Summit and Awards 2025
Jan 9, 2025 15:17 HKT/SGT
|
|
|
Sparkline Hosts Exclusive Webinar on Leveraging Google Analytics 4 for E-Commerce Success
Jan 9, 2025 13:00 HKT/SGT
|
|
|
China Medical System (00867) Obtained New Drug ZUNVEYL for the Treatment of Mild-to-Moderate Dementia of the Alzheimer's Type
Jan 9, 2025 08:00 HKT/SGT
|
|
|
Biotech Startups Get a Boost: ZAGENO and Hatch.Bio Labs Partner to Streamline Lab Operations
Jan 8, 2025 22:30 HKT/SGT
|
|
|
'Behind the Canvas Series 1: Jean-Michel Basquiat' Makes Its Global Debut in Singapore
Jan 8, 2025 17:00 HKT/SGT
|
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|
